Paclitaxel-Eluting vs. Sirolimus-Eluting Balloons

Coronary restenosis remains one of the main challenges in percutaneous transluminal coronary angioplasty (PTCA), especially nowadays, when procedures are increasingly complex and more stents are used, particularly in older patients.

Drug-eluting balloons (DEB) have proven to be beneficial in this scenario, according to several studies. Currently, there are paclitaxel- and sirolimus-eluting balloons, each with distinct characteristics. However, it is still unclear which of these drugs is superior or which circumstances would make one or the other more appropriate to use.

Researchers conducted a meta-analysis that included 1861 patients (from 5 randomized studies and 3 observational studies). Of these, 889 received paclitaxel-eluting balloons (PEB) and the rest received sirolimus-eluting balloons (SEB). Both de novo lesions and restenosis cases were included.

The assessment included clinical and angiographic events between 6 and 12 months of follow-up.

There were no significant differences between the groups in terms of the composite of cardiac death, myocardial infarction, or target vessel failure (odds ratio [OR] 1.01; 95% confidence interval [CI]: 0.75–1.35; I² = 0.0%). There were also no differences in cardiac mortality, myocardial infarction, or need for target lesion revascularization (TLR), which was consistent across both randomized and observational studies.

Read also: Plaque Morphology and Stent Elongation Assessed by OCT.

In the angiographic follow-up, patients who received PEB had a larger minimum luminal diameter compared to those who received SEB (0.10 mm, 95% CI: 0.02–0.17). This difference was more pronounced in de novo lesions than in restenosis cases.

Late lumen loss (the difference between the minimum luminal diameter during the procedure and at follow-up angiography) was also lower in patients treated with PEB compared with those who received SEB (-0.11 mm, 95% CI: -0.23 to 0.02; I² = 57.1%), although this difference was not statistically significant.

Conclusion:

At 9 and 12 months of follow-up, the rate of target lesion failure (TLF) was similar between the PEB and SEB groups. However, in the angiographic follow-up, the minimum luminal diameter was greater in patients who received PEB.

Original Title: Paclitaxel‐coated versus sirolimus‐coated balloon angioplasty for coronary artery disease: A systematic review and meta‐analysis.

Reference: Doosup Shin, et al. Catheter Cardiovasc Interv. 2024;104:425–436.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | TUXEDO-2: Post-PCI Antiplatelet Management in Diabetic Patients with Multivessel Disease — Ticagrelor or Prasugrel?

Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI) remains a major clinical challenge. These...

AHA 2025 | DECAF: Coffee Consumption vs. Abstinence in Patients with Atrial Fibrillation: Recurrence or Myth?

The link between coffee consumption and arrhythmia has been met with contradicting recommendations. It is widely believed that caffeine could trigger atrial fibrillation (AF)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | CLOSURE-AF: Left Atrial Appendage Occlusion (LAAO) vs. Medical Therapy in Atrial Fibrillation with High Stroke and Bleeding Risk

Atrial fibrillation (AF) is a complex condition in which patients often present with multiple comorbidities, including high bleeding risk. Percutaneous left atrial appendage occlusion...